Latest news with #NasusPharma
Yahoo
2 days ago
- Business
- Yahoo
Nasus Pharma Announces Closing of Initial Public Offering
TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ('Nasus Pharma' or the 'Company'), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the closing of its initial public offering of 1,250,000 ordinary shares ('Ordinary Shares') at a public offering price of $8.00 per Ordinary Share. The gross proceeds of the offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Nasus Pharma's shares began trading on the NYSE American LLC exchange on August 13, 2025 under the ticker symbol 'NSRX'. Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, to purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions. The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures. Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC acted as Joint Bookrunners for the offering. A registration statement on Form F-1 (File No. 333-288582) (the 'Registration Statement') relating to the initial public offering was filed with the Securities and Exchange Commission ('SEC') and declared effective by the SEC on August 12, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities referred to herein nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus forming a part of the Registration Statement. A copy of the final prospectus relating to this offering has been filed with the SEC and copies of the final prospectus can be obtained by contacting Laidlaw & Company (UK) Ltd., 521 Fifth Ave, 12th Floor, New York, NY 10075, or by calling 212-953-4900 or by e-mailing syndicate@ About Nasus Pharma Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal ('PBI') technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. Forward Looking Statements This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements related to the expected use of proceeds from the Company's initial public offering. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' "will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the final prospectus related to the initial public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contactinfo@ Pharma Ltd. Israelhttps:// Investor ContactMike MoyerLifeSci Advisors+1-617-308-4306mmoyer@
Yahoo
4 days ago
- Business
- Yahoo
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ('Nasus Pharma' or the 'Company'), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the pricing of its initial public offering of 1,250,000 ordinary shares ('Ordinary Shares') at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses and excluding any exercise of the underwriters' option to purchase any additional securities as described herein. In addition, Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions, to cover the over-allotment, if any. The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures. In connection with the offering, Nasus Pharma's Ordinary Shares have been approved for listing on the NYSE American LLC. The Ordinary Shares are expected to begin trading on the NYSE American LLC on August 13, 2025 under the ticker symbol "NSRX". The offering is expected to close on August 14, 2025, subject to customary closing conditions. Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC are acting as Joint Bookrunners for the offering. A registration statement on Form F-1 (File No. 333-288582) (the 'Registration Statement') relating to the initial public offering was filed with the Securities and Exchange Commission ('SEC') and declared effective by the SEC on August 12, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities referred to herein nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of a prospectus forming a part of the Registration Statement. A copy of the final prospectus relating to this offering, when available, will be filed with the SEC and may also be obtained from Laidlaw & Company (UK) Ltd., 521 Fifth Ave, 12th Floor, New York, NY 10075, or by calling 212-953-4900 or by emailing syndicate@ About Nasus Pharma Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal ('PBI') technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. Forward Looking Statements This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things, statements related to the initial public offering, the expected use of proceeds from such offering, the expected start of trading of the Company's ordinary shares on the NYSE American and the expected closing date of the offering. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' "will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Registration Statement final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contactinfo@ Pharma Ltd. Israelhttps:// Investor ContactMike MoyerLifeSci Advisors+1-617-308-4306mmoyer@
Yahoo
03-06-2025
- Business
- Yahoo
Nasus Pharma Announces the Publication of Positive Clinical Results from its Phase 2 Study of FMXIN002 (NS002) Intranasal Epinephrine Powder
TEL AVIV, Israel, June 3, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based intranasal ("PBI") products addressing acute, community based, medical emergencies, today announced the publication of its phase 2 NS002 clinical study performed at the Clinical Research Unit of Hadassah Medical Center in The Journal of Allergy and Clinical Immunology (Global). NS002 is an Epinephrine powder nasal spray for the treatment of type 1 severe allergies and anaphylaxis. The published article (J Allergy Clin Immunol Global 2025;4:100487) explored the comparative bioequivalence of different dosages of intranasal powder Epinephrine (3.6 and 4 mg) compared to the current standard of care, 0.3 mg EpiPen (Epinephrine intramuscular ("IM") autoinjector). This was an open-label, single-dose, 3-treatment, crossover, randomized study that included 12 healthy volunteers. The study results demonstrated that FMXIN002 (NS002) 4.0 mg had faster and higher absorption by all participants, compared to the IM autoinjector: 91% of subjects achieved the hemodynamic clinical threshold of 100 pg/mL plasma Epinephrine at 6 minutes after administration of FMXIN002(NS002) 4.0 mg compared to 55% of subjects receiving the IM autoinjector. The absorption area under the curve for the first 4 minutes was significantly higher for NS002 4.0 mg (geometric mean: 7.49 h/pg/mL vs 2.06 h/pg/mL, respectively; P= 0.0377). The pharmacodynamic response and safety were comparable among all treatments. No serious adverse events occurred, all events were mild and self-resolved. FMXIN002(NS002) was highly stable at all tested conditions including 5 years at room temperature. Prof. Yuval Tal, Head of Allergy and Clinical Immunology Clinic at Hadassah Medical Center commented: "This study demonstrates that FMXIN002 (NS002) intranasal Epinephrine powder could enable faster and higher absorption of Epinephrine into the plasma during the short therapeutic window required for the treatment of anaphylaxis. I have followed the development of NS002 since its first in-human study and am excited about its potential as a simple, convenient, needle free alternative to IM Epinephrine. Intranasal Epinephrine dry powder represents a transformative advancement in anaphylaxis treatment. Unlike traditional autoinjectors - which are unavailable in many countries, require frequent replacement and often deter use due to needle phobia - this needle-free, compact, and user-friendly formulation could potentially offer in the future an alternative with a shelf life exceeding five years. Its design could facilitate easy and rapid administration, and its portability could allow individuals to carry multiple doses effortlessly. By addressing the limitations of current treatments, this innovation could have the potential to significantly improve accessibility and adherence, ultimately saving lives in emergency situations." About FMXIN002 (NS002) FMXIN002, also known as NS002, is a powder formulation of Epinephrine nasal spray developed by Nasus Pharma based on its unique intranasal powder proprietary technology. The Company believes that FMXIN002 (NS002) may enable people to deliver Epinephrine in emergency situations easily, rapidly, and with less hesitation, at the onset of an allergic reaction, as compared to currently available Epinephrine autoinjectors. FMXIN002 uses Aptar Pharma's Unidose nasal powder unit dose spray device – an intuitive and easy-to-use device with 360° functionality and precise one-dose nasal drug delivery. Anaphylaxis is a severe, life-threatening allergic reaction with a sudden onset that can occur within a few minutes, and unless treated promptly, could be fatal. There are approximately 40 million patients with type 1 allergies in the United States alone, of which approximately 20 million patients who experience severe type 1 allergic reactions that may lead to anaphylaxis. About Nasus Pharma Ltd. Based on its unique microsphere technology, Nasus Pharma is developing a number of intranasal powder products addressing acute emergency situations in the community such as anaphylactic shock and opioid overdose. Intranasal administration is most suitable for those situations in which rapid treatment is required and could offer multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety. Nasus Pharma's portfolio comprises a number of programs in different stages of development. Forward Looking Statements This press release contains express or implied forward-looking statements. For example, the Company is using forward-looking statements when it discusses FMXIN002 (NS002) its development and potential benefits. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Contact: Info@ Nasus Pharma Ltd. Israelhttps:// Logo - View original content: SOURCE Nasus Pharma
